The effect of therapy based on the use of ultra-low doses of antibodies to the C-terminal fragment of the beta subunit of the insulin receptor and antibodies to endothelial NO-synthase on the functional state of the liver in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease